AFT Pharmaceuticals Ltd (AX:AFP) is a New Zealand-based specialty pharmaceutical company that currently sells 130 prescription specialty generics and OTC products through its own salesforce in New Zealand, Australia and South-East Asia and has been expanding its geographic footprint. AFT now has agreements in 109 countries to distribute Maxigesic, its combination paracetamol (acetaminophen)/ibuprofen product. We value AFT at NZ$458m or NZ$4.73 per basic share.
A diversified company with a great track record
Founded in 1997, AFT Pharmaceuticals has grown to a large regional specialty pharmaceutical company selling over 130 proprietary and in-licensed products, covering a wide range of therapeutic categories in the hospital, prescription and OTC markets. AFT lowers its overall risk by steering away from drug development of new chemical entities and instead focuses on improving existing treatments.
To read the entire report Please click on the pdf File Below